Drugs / Alpha-1 HC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01684410 | Aug 2012 → Oct 2013 | cystic fibrosis | Grifols Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-1 HC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01684410 ↗ |
| Modality | Protein / enzyme biologic | “purified alpha1-proteinase inhibitor prepared from pooled human plasma” NCT01684410 ↗ |
| Route | Inhaled | “Alpha-1 HC 100 mg inhaled once daily for 21 days” NCT01684410 ↗ |